🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Vonoprazan

    Phathom Pharmaceuticals

    Non-Erosive Gastro-Esophageal Reflux Disease

    phase 3 small molecule completed

    2 trials
  2. Vosoritide

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 3 small molecule active

    3 trials
  3. Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection, Voxzogo 1.2 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 3 small molecule active

    1 trial
  4. Voxzogo 1.2 mg powder and solvent for solution for injection, Voxzogo 0.4 mg powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 3 small molecule active

    1 trial
  5. Voxzogo 1.2 mg powder and solvent for solution for injection, powder and solvent for solution for injection, Voxzogo 0.56 mg powder and solvent for solution for injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 3 small molecule active

    1 trial
  6. Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo

    Astellas Pharma GmbH

    Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial
  7. Vyxeos

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial
  8. Walvax PCV13-TT

    Biotech Pharmaceutical Co.,

    Pneumococcal Disease, Invasive

    phase 3 mab active

    1 trial
  9. White opaque capsule filled with a white to off- white powder, eRapa

    Biodexa Pharmaceuticals Plc

    Familial adenomatous polyposis (FAP)

    phase 3 small molecule active

    1 trial
  10. XEN1101

    Xenon Pharmaceuticals

    Focal Onset Seizures

    phase 3 small molecule active

    2 trials
  11. XEN1101

    Xenon Pharmaceuticals

    Primary Generalized Tonic-Clonic Seizures

    phase 3 small molecule active

    1 trial
  12. XEN1101

    Xenon Pharmaceuticals

    Focal Epilepsy

    phase 3 small molecule active

    2 trials
  13. XEN45

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 other completed

    1 trial
  14. XEN496

    Xenon Pharmaceuticals

    Epilepsy

    phase 3 small molecule terminated

    2 trials
  15. XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial
  16. XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań

    Merz Pharmaceuticals GmbH

    Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)

    phase 3 small molecule active

    1 trial
  17. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial
  18. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial
  19. XPF-010

    Xenon Pharmaceuticals

    Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)

    phase 3 small molecule active

    1 trial
  20. XPF-010, Placebo to match XPF-010

    Xenon Pharmaceuticals

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial
  21. Xylocore Medium Strength, bicaVera 4,25 % Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, Xylocore High Strength, PHYSIONEAL 40 Glucose 3,86 % w/v / 38,6 mg/ml, Peritonealdialyselösung, balance 4,25% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL 35 Glucose 1,36 % w/v / 13,6 mg/ml, Peritonealdialyselösung, FIXIONEAL “35 Glucosio 3,86% p/v/38,6 mg/ml” in sacca Clear-Flex Soluzione per dialisi peritoneale, balance 2,3% Glucose, 1,75 mmol/l Calcium, Peritonealdialyselösung, PHYSIONEAL

    Lacuna Pharma Pty Ltd

    End-Stage Kidney Disease

    phase 3 small molecule active

    1 trial
  22. Xyrem

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 3 small molecule completed

    1 trial
  23. Xyrem

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy With Cataplexy

    phase 3 small molecule completed

    1 trial
  24. Xyrem (sodium oxybate) oral solution

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources